| Patients enrolled | Full analysis set, V0 n=149 | Full analysis set, V1 n=147 | Full analysis set, V2 n=143 | Full analysis set, V3 n=134 | Full analysis set, V4 n=128 |
|-------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|
| N=155             | Discontinued adalimumab, n=3 | Discontinued adalimumab, n=6 | Discontinued adalimumab, n=10 | Discontinued adalimumab, n=16 |
|                   | AESI, n=2                    | AE, n=1                     | AE, n=2                     | AE, n=2                     |
|                   | Investigator decision, n=1   | Lost to follow-up, n=1      | Lost to follow-up, n=2      | Lost to follow-up, n=5      |
|                   | Missing, n=1                 | Investigator decision, n=1  | Patient request, n=2        | Investigator decision, n=4  |
|                   | Patient request, n=2        | Missing, n=1               | Patient request, n=2        | Patient request, n=4        |
|                   |                              |                              |                              |                              |

Criteria and had data for ≥1 follow-up visit.